AtaiBeckley Inc. (NASDAQ:ATAI) shares are up on Wednesday following the announcement of promising Phase 2a results for its treatment-resistant depression drug, BPL-003.
Depression Drug Shows Sustained Antidepressant Response
The company reported a 66.7% antidepressant response rate at Day 2, which has contributed to the stock's upward momentum as broader markets experienced gains on Tuesday.
AtaiBeckley announced that a single intranasal dose of BPL-003 achieved significant reductions in MADRS scores among participants with treatment-resistant depression, with 83% of patients maintaining a response at Week 12.
BPL-003 was generally well tolerated with no serious adverse events reported, and participants achieved a mean discharge time of approximately 100 minutes post-dose.
The company is on track to initiate Phase 3 studies in the second quarter of 2026, following recent FDA alignment.
Pipeline Progress Includes EMP-01 In Social Anxiety Disorder
In February, AtaiBeckley shared topline results from an exploratory Phase 2a trial of EMP-01, an oral R-MDMA treatment for Social Anxiety Disorder.
In the trial, 49% of patients receiving EMP-01 were rated as "very much improved" or "much improved," compared to only 15% in the placebo group, indicating a clinically meaningful improvement.
AtaiBeckley Technical Setup Signals Near-Term Momentum With Mixed Trend
At $4.09, the stock is trading 12.8% above its 20-day simple moving average (SMA) and 6% above its 100-day SMA, suggesting strong short-term momentum.
However, the 50-day SMA is still below the current price, indicating a mixed trend in the intermediate term.
The relative strength index (RSI) is at 53.63, which is neutral and suggests that the stock is neither overbought nor oversold. This positioning indicates a balanced buyer-seller dynamic, allowing for potential upward movement if positive sentiment continues.
- Key Resistance: $4.50 — A level where selling pressure may increase.
- Key Support: $3.50 — A level where buying interest could emerge.
The stock has shown a remarkable 12-month performance of 213.22%, reflecting strong long-term growth potential.
Currently, it is trading near the midpoint of its 52-week range, which suggests that while there is room for growth, the stock is not at an extreme high or low.
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $14.20. Recent analyst moves include:
- Deutsche Bank: Initiated with Buy (Target $12.00) (March 27)
- HC Wainwright & Co.: Buy (Maintains Target to $25.00) (March 17)
- Needham: Buy (Maintains Target to $14.00) (March 9)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for AtaiBeckley, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bullish (Score: 91.36) — Stock is outperforming the broader market.
The Verdict: AtaiBeckley's Benzinga Edge signal reveals a strong momentum-driven story, reflecting its recent positive developments and potential for growth in a challenging sector.
ATAI Price Action: AtaiBeckley shares were up 0.13% at $3.79 at the time of publication on Wednesday, according to Benzinga Pro data.
Image via Shutterstock